Alector, Inc. last reported quarterly results on Oct 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $162.9 million (+4895.9% year over year) and diluted EPS of $1.11. It usually reports 5–56 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 24, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 25, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 5–56 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 5, 2026
5 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
163
+4895.9%
|
125
+459.4%
|
1.11
+426.5%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
3
-57.8%
|
-23
+24.7%
|
-0.21
+30.0%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
-71.5%
|
-23
+43.3%
|
-0.21
+48.8%
|
|
Feb 25, 2026
56 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
6
-88.5%
|
-37
-1696.9%
|
-0.34
-1513.3%
|
|
Oct 21, 2025
21 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3
-78.8%
|
-35
+17.9%
|
-0.34
+20.9%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
8
-47.8%
|
-31
+21.1%
|
-0.30
+25.0%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
4
-76.9%
|
-40
-12.2%
|
-0.41
-7.9%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
54
+257.1%
|
-2
+95.0%
|
-0.02
+95.7%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ALEC (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1653087
- Former names
- Alector LLC (until Sep 16, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.